Tejashree Waghule

Tejashree Waghule

Auto-generated profile, based on publicly available information

Tejashree Waghule

Birla Institute of Technology and Science

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
TWTejashree Waghule
Tejashree Waghule
GSGautam Singhvi
Gautam Singhvi
SDSunil Kumar Dubey
Sunil Kumar Dubey
MPMurali Monohar Pandey
Murali Monohar Pandey
GGGaurav Gupta
Gaurav Gupta
Kamal DuaKamal Dua
Kamal Dua
The most widely used methods for transdermal administration of the drugs are hypodermic needles, topical creams, and transdermal patches. The effect of most of the therapeutic agents is limited due to the stratum corneum layer of the skin, which serves as a barrier for the molecules and thus only a few molecules are able to reach the site of action. A new form of delivery system called the microneedles helps to enhance the delivery of the drug through this route and overcoming the various problems associated with the conventional formulations. The primary principle involves disruption of the skin layer, thus creating micron size pathways that lead the drug directly to the epidermis or upper dermis region from where the drug can directly go into the systemic circulation without facing the barrier. This review describes the various potential and applications of the microneedles. The various types of microneedles can be fabricated like solid, dissolving, hydrogel, coated and hollow microneedles. Fabrication method selected depends on the type and material of the microneedle. This system has increased its application to many fields like oligonucleotide delivery, vaccine delivery, insulin delivery, and even in cosmetics. In recent years, many microneedle products are coming into the market. Although a lot of research needs to be done to overcome the various challenges before the microneedles can successfully launch into the market.

24 July 2020 in RSC Advances
Verified
Journal Article
Open access
PDF file
SGSrividya Gorantla
Srividya Gorantla
VRVamshi Krishna Rapalli
Vamshi Krishna Rapalli
TWTejashree Waghule
Tejashree Waghule
PSPrem Prakash Singh
Prem Prakash Singh
SDSunil Dubey
Sunil Dubey
GSGautam Singhvi
Gautam Singhvi
Ocular diseases have a significant effect on vision and quality of life.

1 August 2019 in Journal of Drug Delivery Science and Technology
Verified
Journal Article
Closed access
TWTejashree Waghule
Tejashree Waghule
VRVamshi Krishna Rapalli
Vamshi Krishna Rapalli
GSGautam Singhvi
Gautam Singhvi
PMPrachi Manchanda
Prachi Manchanda
NHNeha Hans
Neha Hans
ANAMIT KUMAR NAYAK
AMIT KUMAR NAYAK

23 October 2020 in Current Pharmaceutical Design
Verified
Journal Article
Closed access
PDF file
TWTejashree Waghule
Tejashree Waghule
VRVamshi Krishna Rapalli
Vamshi Krishna Rapalli
SGSrividya Gorantla
Srividya Gorantla
RSRanendra Narayan Saha
Ranendra Narayan Saha
SDSunil Dubey
Sunil Dubey
GSGautam Singhvi
Gautam Singhvi
Background: Skin diseases affect all the age groups of people and have an impact on patients’ physical, mental, and emotional status. Conventional topical preparation is limited with its efficacy due to low permeation, frequent application, and poor adherence to the therapy for prolong time. Objective: The objective of this review article is to address the emerging trends of nanotechnology derived lipidic carrier systems for an effective treatment for skin disorders. Methodology: Various research and review articles from reputed international journals were referred and compiled. Results and Discussion: opical drug delivery systems were found to be more effective than oral and parenteral drug delivery systems for treating skin diseases due to targeted localized applications with reduced side effects. Lipid-based nanoparticles have been found to have the potential in treating skin diseases due to the biocompatibility and the versatility of the lipids. Nanostructured lipid carriers (NLCs) have gained much attention in treating skin diseases due to improved stability of the drugs, enhanced skin permeation, retention, and better therapeutic efficacy. The review summarizes the NLCs characteristics and their application for topical delivery of various therapeutics in skin disorders. NLCs have shown great potential in effective drug delivery for the treatment of psoriasis, dermatitis, bacterial infections, and skin cancer. Its cosmetic application has opened a new area for skincare. Furthermore, safety and clinical status revealed its future commercial acceptability. Conclusion: NLCs have been found as effective lipid nanocarriers for the delivery of topical therapeutics.

1 October 2021 in Journal of Molecular Liquids
Verified
Journal Article
Closed access
NDNeha Dabholkar
Neha Dabholkar
TWTejashree Waghule
Tejashree Waghule
VRVamshi Krishna Rapalli
Vamshi Krishna Rapalli
SGSrividya Gorantla
Srividya Gorantla
AAAmit Alexander
Amit Alexander
GSGautam Singhvi
Gautam Singhvi

3 April 2020 in Journal of Liposome Research
Verified
Journal Article
Closed access
TWTejashree Waghule
Tejashree Waghule
VRVamshi Krishna Rapalli
Vamshi Krishna Rapalli
GSGautam Singhvi
Gautam Singhvi
SGSrividya Gorantla
Srividya Gorantla
AKArchana Khosa
Archana Khosa
RSRanendra Narayan Saha
Ranendra Narayan Saha
Temozolomide is a drug approved for treating glioblastomas which has 100% oral bioavailability but gets degraded at physiological pH thus having very short half-life and only 20-30% brain bioavailability. Due to its amphiphilic nature, reported nanoformulations exhibits poor drug loading. The objective of the present work was to formulate lipid-based drug delivery systems to enhance the brain bioavailability by prolonging the drug release and circulation time of the drug to overcome the limitations of the existing therapies and possible reduction of side effects. The size of the nanocarriers obtained was less than 300 nm and the PDI obtained was less than 0.3. The designed formulation showed higher entrapment efficiency as compared to the other reported nanocarriers of temozolomide. The designed formulations showed prolonged drug release from 12 to 20 h compared to 6 h for the pure drug. About 95% of the pure drug was degraded at plasma pH at the end of 12 h whereas only 68% and 77% was degraded when entrapped inside the lipid crystal nanoparticles and proliposomes respectively. Further, pharmacokinetic and animal studies can confirm the potential of these for improvement of brain bioavailability.